Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

RVU120 as a single agent showed clinical benefit in heavily pretreated patients with AML and HR-MDS in the Phase 1 RIVER-51 study (CLI120-001). The strongest evidence of benefit was observed in patients with NPM1 and/or DNMT3A mutations and in patients with HR-MDS. A complete remission…

Leave a Reply

Your email address will not be published. Required fields are marked *